The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 8-U.S. authorizes Moderna COVID-19 vaccine, elderly next in line for shots

Sat, 19th Dec 2020 00:44

(Adds comments from president-elect, infectious disease expert)

By Michael Erman

Dec 18 (Reuters) - Moderna Inc's coronavirus
vaccine on Friday became the second to receive emergency use
authorization (EUA) from the U.S. Food and Drug Administration,
welcome news to a nation with a staggering COVID-19 death toll
of over 307,000 lives lost.

Millions of doses of the Moderna vaccine are expected to be
added to the U.S. rollout, which began this week with healthcare
workers. Older people in long-term care facilities are next in
line for vaccines, with a U.S. Centers for Disease Control and
Prevention expert panel on Sunday set to recommend what groups
follow, as industries compete to have their workers given
precedence.

The FDA announced the authorization the day after the
agency's panel of outside experts endorsed its use and a week
after the FDA authorized a vaccine from Pfizer Inc and
German partner BioNTech SE.

The vaccine from Pfizer and BioNTech, based on similar
technology, has been put into the arms of thousands of U.S.
healthcare workers this week in a massive nationwide rollout.
Moderna injections are expected to begin in coming days for
adults 18 years old and up.

"With the availability of two vaccines now for the
prevention of COVID-19, the FDA has taken another crucial step
in the fight against this global pandemic that is causing vast
numbers of hospitalizations and deaths in the United States each
day,” FDA Commissioner Stephen M. Hahn, M.D, said in a
statement.

Moderna's shot is expected to be used in harder-to-reach
locations, such as rural hospitals. The vaccine needs to be
stored and shipped frozen, but does not require the ultra-cold
temperatures of the Pfizer/BioNTech shot.

The speed of vaccine development - less than a year from
when the first case of the new coronavirus was found in the
United States - is a stunning scientific success, although there
is some hesitancy among the public.

"It is my hope that all Americans will protect themselves by
getting vaccinated when the vaccine becomes available to them.
That is how our country will begin to heal and move forward,"
top U.S. infectious disease scientist Anthony Fauci said in a
statement.

Moderna said it intended to apply for full U.S. license in
2021.

The FDA decision marks the first regulatory authorization in
the world for Moderna's vaccine and validation of its messenger
RNA technology, shown to be nearly 95% effective with no serious
safety concerns. It came less than a year after the
first COVID-19 case was identified in the United States.

The vaccine, developed in partnership with the National
Institutes of Health, had relatively minor side effects
including pain around the injection site and swelling.

The biotech company has worked with the U.S. government to
prepare for the distribution of 5.9 million shots starting as
early as this weekend.

Once thawed, the Moderna vaccine can be kept at typical
refrigerator temperatures. It is administered in two shots 28
days apart.

Between the two vaccines, the United States is expecting 40
million doses before year end, enough to eventually vaccinate 20
million people, as both require two shots.

"Brighter days lie ahead," responded U.S. President-elect
Joe Biden, who plans to be vaccinated on Monday.

U.S. President Donald Trump on Twitter hailed the
authorization. "Congratulations, the Moderna vaccine is now
available!" he wrote. The vaccine must be transported to
hospitals and other centers before injections begin.

Moderna said it would deliver approximately 20 million doses
to the U.S. government this year and expected to have between
100 million and 125 million globally in the first quarter of
next year, with 85-100 million of those for the United States.

Moderna has deals with the U.S. government to provide a
total of 200 million doses by the end of June 2021. Other
vaccines still are in testing, including a one-shot injection
from Johnson & Johnson, and a two-shot course from AstraZeneca
and Oxford University.

U.S. hospitalizations and deaths have surged, driven by last
month's Thanksgiving holiday gatherings. Authorities have
renewed restrictions and shutdowns across the country.

Public health officials have warned infections from
Christmas and New Year's celebrations could exacerbate a crisis
that already threatens to overwhelm healthcare systems
nationwide.

Even with two highly effective vaccines, practices such as
social distancing and face covering will be needed for months
before enough people are inoculated to curb virus transmission
and eventually end the pandemic.

"With strong federal funding for swift vaccine rollout and
education, and by following the guidance of public health
experts to continue wearing masks and maintaining distance, we
can bring the end of this pandemic closer," Barbara Alexander,
head of the Infectious Diseases Society of America, said in a
statement.
(Reporting by Reporting by Kanishka Singh and Manojna
Maddipatla in Bengaluru, Michael Erman and Rebecca Spalding in
New York, Peter Henderson in Oakland and Julie Steenhuysen in
Chicago; Editing by Caroline Humer, Bill Berkrot and David
Gregorio)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.